HRP970246A2 - Substituted oxobutric acids as matrix metalloprotease inhibitors - Google Patents

Substituted oxobutric acids as matrix metalloprotease inhibitors

Info

Publication number
HRP970246A2
HRP970246A2 HR08/648,384A HRP970246A HRP970246A2 HR P970246 A2 HRP970246 A2 HR P970246A2 HR P970246 A HRP970246 A HR P970246A HR P970246 A2 HRP970246 A2 HR P970246A2
Authority
HR
Croatia
Prior art keywords
oxobutric
acids
substituted
matrix metalloprotease
metalloprotease inhibitors
Prior art date
Application number
HR08/648,384A
Inventor
Brian R Dixon
Jinshan Chen
Michael Van Zandt
David R Brittelli
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of HRP970246A2 publication Critical patent/HRP970246A2/en
Publication of HRP970246B1 publication Critical patent/HRP970246B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/90—Unsaturated compounds containing keto groups containing singly bound oxygen-containing groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/08—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 condensed with carbocyclic rings or ring systems
HR970246A 1996-05-15 1997-05-09 Substituted oxobutric acids as matrix metalloprotease inhibitors HRP970246B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US64838496A 1996-05-15 1996-05-15

Publications (2)

Publication Number Publication Date
HRP970246A2 true HRP970246A2 (en) 1998-04-30
HRP970246B1 HRP970246B1 (en) 2002-04-30

Family

ID=24600568

Family Applications (1)

Application Number Title Priority Date Filing Date
HR970246A HRP970246B1 (en) 1996-05-15 1997-05-09 Substituted oxobutric acids as matrix metalloprotease inhibitors

Country Status (18)

Country Link
EP (1) EP0912487A1 (en)
JP (1) JP3417951B2 (en)
CN (1) CN1163466C (en)
AR (1) AR007096A1 (en)
AU (1) AU727648B2 (en)
CA (1) CA2253869C (en)
CO (1) CO4990925A1 (en)
HR (1) HRP970246B1 (en)
ID (1) ID20291A (en)
MY (1) MY132470A (en)
PA (1) PA8429401A1 (en)
PE (1) PE65998A1 (en)
SV (1) SV1997000034A (en)
TN (1) TNSN97085A1 (en)
TW (1) TW467892B (en)
WO (1) WO1997043238A1 (en)
YU (1) YU18797A (en)
ZA (1) ZA974032B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6288063B1 (en) 1998-05-27 2001-09-11 Bayer Corporation Substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors
GB0321538D0 (en) 2003-09-13 2003-10-15 Glaxo Group Ltd Therapeutically useful compounds
CA2696041A1 (en) * 2007-08-15 2009-02-19 Kyorin Pharmaceutical Co., Ltd. Preventive, inhibitor or remedy for cerebral aneurysm comprising ibudilast as an active ingredient
CA2944614A1 (en) 2014-04-03 2015-10-08 Bayer Pharma Aktiengesellschaft 2,5-disubstituted cyclopentane carboxylic acids for the treatment of respiratoy tract diseases
CN106458938A (en) 2014-04-03 2017-02-22 拜耳制药股份公司 Chiral 2,5-disubstituted cyclopentanecarboxylic acid derivatives and use thereof
EP3126339A1 (en) 2014-04-03 2017-02-08 Bayer Pharma Aktiengesellschaft 2,5-disubstituted cyclopentane carboxylic acids and use thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3827324B2 (en) * 1994-01-22 2006-09-27 ブリテッシュ バイオテック ファーマシューティカルズ リミテッド Metalloproteinase inhibitor

Also Published As

Publication number Publication date
AU3121997A (en) 1997-12-05
SV1997000034A (en) 1999-07-05
CN1225622A (en) 1999-08-11
ZA974032B (en) 1998-02-19
HRP970246B1 (en) 2002-04-30
CN1163466C (en) 2004-08-25
CA2253869C (en) 2003-04-22
TW467892B (en) 2001-12-11
CO4990925A1 (en) 2000-12-26
PE65998A1 (en) 1998-10-20
YU18797A (en) 1999-11-22
WO1997043238A1 (en) 1997-11-20
EP0912487A1 (en) 1999-05-06
CA2253869A1 (en) 1997-11-20
ID20291A (en) 1998-11-19
MY132470A (en) 2007-10-31
TNSN97085A1 (en) 2005-03-15
JPH11509870A (en) 1999-08-31
AU727648B2 (en) 2000-12-21
PA8429401A1 (en) 2000-05-24
JP3417951B2 (en) 2003-06-16
AR007096A1 (en) 1999-10-13

Similar Documents

Publication Publication Date Title
IL128668A0 (en) Phosphinic acid amides as matrix metalloprotease inhibitors
ZA959948B (en) Matrix metalloprotease inhibitors
PL331254A1 (en) Phosphonianic inhibitors of matrix metaloproteases
IL128663A0 (en) 1,4-heterocyclic metalloprotease inhibitors
IL128661A0 (en) 1,3-diheterocyclic metalloprotease inhibitors
AU3102397A (en) Metalloprotease inhibitors
HU9801045D0 (en) Substituted diamino-carboxylic acids
AU4201799A (en) Substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors
IL128665A0 (en) Bidenatate metalloprotease inhibitors
ZA96850B (en) Matrix metalloprotease inhibitors.
GB9613547D0 (en) Matrix metalloproteinase inhibitors
IL129420A0 (en) Substituted 4-biphenyl-4-hydroxybutyric acid derivatives as matrix metalloprotease inhibitors
HK1021897A1 (en) Inhibition of matrix metalloproteases by 2-substituted-4-(4-substitutedphenyl)-4-oxobutyric acids
HUP0101300A3 (en) Matrix metalloprotease inhibitors
IL115995A0 (en) Substituted 4-biarylbutyric or 5-biarylpentanoic acids and derivatives as matrix metalloprotease inhibitors
IL137162A0 (en) 2,3,4,5-tetrahydro -1h- [1,4]-benzodiazepine -3- hydroxamic acids as matrix metalloproteinase inhibitors
HRP970245A2 (en) Biaryl acetilenes as matrix metalloprotease inhibitors
HRP970247A2 (en) Substituted 4-arylbutric acid derivatives as matrix metalloprotease inhibitors
HRP970246A2 (en) Substituted oxobutric acids as matrix metalloprotease inhibitors
ZA9610604B (en) Matrix metalloprotease inhibitors
GB9702085D0 (en) Matrix metalloproteinase inhibitors
SI0901466T1 (en) Biphenylsulfonamide matrix metalloproteinase inhibitors
GB9415619D0 (en) Metalloprotease inhibitors
SI0790974T1 (en) Substituted 4-biarylbutyric or 5-biarylpentanoic acids and derivatives as matrix metalloprotease inhibitiors
GB9602268D0 (en) Naphthyl glyoxamides as sPLA2 inhibitors

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20040428

Year of fee payment: 8

PBON Lapse due to non-payment of renewal fee

Effective date: 20050510